

10773588

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2.

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

Updated Search

10773588

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:09:36 ON 26 SEP 2006

=> file regf

'REGF' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'HOME'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:09:47 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\6767e.str

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 15:10:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4265 TO ITERATE

46.9% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

Updated Search

10773588

PROJECTED ITERATIONS: 81384 TO 89216
PROJECTED ANSWERS: 4 TO 345

L2 4 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:10:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 87152 TO ITERATE

100.0% PROCESSED 87152 ITERATIONS 202 ANSWERS
SEARCH TIME: 00.00.01

L3 202 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	167.59

FILE 'HCAPLUS' ENTERED AT 15:10:56 ON 26 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.53	170.12

FILE 'REGISTRY' ENTERED AT 15:10:59 ON 26 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

Updated Search

10773588

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\6767e.str

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 15:12:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4265 TO ITERATE

46.9% PROCESSED 2000 ITERATIONS 4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 81384 TO 89216

PROJECTED ANSWERS: 4 TO 345

L5 4 SEA SSS SAM L4

=> s l4 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 15:12:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 87152 TO ITERATE

100.0% PROCESSED 87152 ITERATIONS

202 ANSWERS

SEARCH TIME: 00.00.01

L6 202 SEA SSS FUL L4

=> d his

(FILE 'HOME' ENTERED AT 15:09:36 ON 26 SEP 2006)

Updated Search

10773588

FILE 'REGISTRY' ENTERED AT 15:09:47 ON 26 SEP 2006

L1 STRUCTURE UPLOADED
L2 4 S L1
L3 202 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:10:56 ON 26 SEP 2006

FILE 'REGISTRY' ENTERED AT 15:10:59 ON 26 SEP 2006

L4 STRUCTURE UPLOADED
L5 4 S L4
L6 202 S L4 FULL

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.70	338.82

FILE 'HCAPLUS' ENTERED AT 15:14:04 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14

FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6

L7 7 L6

=> s l7 and chupak, l?/au

16 CHUPAK, L?/AU

L8 3 L7 AND CHUPAK, L?/AU

=> d l8, ibib abs hitstr, 1-3

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:681569 HCAPLUS

DOCUMENT NUMBER: 141:207197

TITLE: Preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.

INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Jiao, Wenhua

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA


Updated Search

10773588

SOURCE: PCT Int. Appl., 162 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069245	A1	20040819	WO 2004-IB231	20040127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2514241	AA	20040819	CA 2004-2514241	20040127
EP 1594495	A1	20051116	EP 2004-705475	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007335	A	20060110	BR 2004-7335	20040127
JP 2006516990	T2	20060713	JP 2006-502378	20040127
<u>US 2005277630</u>	A1	20051215	US 2004-772860	20040206
PRIORITY APPLN. INFO.:			US 2003-445909P	P 20030207
			WO 2004-IB231	W 20040127

OTHER SOURCE(S): MARPAT 141:207197
 GI



AB Title compds. I [A = O, NH, S; B = COR1, CSR1, heterocyclo, etc.; R1 = H, alkyl, cycloalkyl, etc.; either D is N, E is C, and F = CH when "----" is a bond, or D = CH, E = N, and F = CH2 when "----" is absent (sic); P = tricyclic ring with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of hydrazine and dimethylaminomethylene II afforded oxazolidinone III in 60% yield. In H. influenzae (HI3542) min. inhibitory concentration (MIC) assays, 8-examples of

10773588

comps. I exhibited MIC values ranging from 4->64 µg/mL, e.g., the MIC value of oxazolidinone III was 8 µg/mL. Compds. I are claimed useful for the treatment of bacterial infections.


IT 741253-96-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 741253-96-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[2-[(dimethylamino)methylene]-1,2,4,5-tetrahydro-3,3-dioxido-1-oxo-3-benzothiepin-7-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 740842-28-8P 741253-88-3P 741253-89-4P

741253-92-9P 741254-17-1P 741254-18-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 740842-28-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 741253-88-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-1-oxo-3-benzothiepin-7-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741253-89-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-1-oxo-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741253-92-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-17-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(4-pyridinylmethylene)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 741254-18-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(dimethylamino)methylene]-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 741254-27-3P 741254-38-6P 741254-39-7P
741254-40-0P 741254-41-1P 741254-43-3P
741254-55-7P 741254-56-8P 741254-57-9P
741254-58-0P 741254-60-4P 741254-61-5P
741254-62-6P 741254-63-7P 741254-64-8P
741254-65-9P 741254-66-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 741254-27-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-bromo-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741254-38-6 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 741254-39-7 HCAPLUS

CN Butanoic acid, [(5R)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-40-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-41-1 HCAPLUS

Updated Search

10773588

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-43-3 HCAPLUS

CN Butanoic acid, [(5R)-2-oxo-3-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-55-7 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-56-8 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741254-57-9 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-58-0 HCAPLUS

CN 1-Benzoxepin-4-carbodithioic acid, 8-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3,4,5-tetrahydro-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-60-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(4-fluorobenzoyl)-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741254-61-5 HCAPLUS

CN	Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(4-pyridinylcarbonyl)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)
----	---


Absolute stereochemistry.



RN 741254-62-6 HCAPLUS

CN Acetamide, N-[[(5S)-3-(4-benzoyl-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-63-7 HCAPLUS

CN Acetamide, N-[[[5S]-2-oxo-3-[2,3,4,5-tetrahydro-4-(5-isoxazolylcarbonyl)-5-oxo-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 741254-64-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(1-oxopropyl)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-65-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-4-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-66-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10773588



L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:681568 HCAPLUS
 DOCUMENT NUMBER: 141:190784
 TITLE: Preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.
 INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Pettersson, Martin Youngjin; Lall, Manjinder Singh; Hagen, Susan Elizabeth; Boyer, Frederick Earl, Jr.
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069244	A1	20040819	WO 2004-IB209	20040127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515269	AA	20040819	CA 2004-2515269	20040127
EP 1594494	A1	20051116	EP 2004-705472	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007304	A	20060110	BR 2004-7304	20040127
JP 2006516989	T2	20060713	JP 2006-502372	20040127
US 2004224939	A1	20041111	US 2004-773588	20040205
PRIORITY APPLN. INFO.:			US 2003-445957P	P 20030207
			WO 2004-IB209	W 20040127
OTHER SOURCE(S):		MARPAT 141:190784		
GI				



AB Title compds. I [A = O, NH, S; B = COR1, CSR1, heterocyclo, etc.; R1 = H, alkyl, cycloalkyl, etc.; either D is N, E is C, and F = CH when "----" is a bond, or D = CH, E = N, and F = CH2 when "----" is absent (sic); P = bicyclic ring, e.g., benzo[b]cycloheptanones, homochromanones, homothiochromanones, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, CrO3/Ac2O mediated oxidation of benzocycloheptane II, e.g., prepared from 1-benzouberone in 5-steps, afforded oxazolidinone III in 14% yield. In H. influenzae (HI3542) min. inhibitory concentration (MIC) assays, 15-examples of compds. I exhibited MIC values ranging from 2->64 µg/mL, e.g., the MIC value of oxazolidinone III was 8 µg/mL. Compds. I are claimed useful for the treatment of bacterial infections.

IT 444587-84-2P 444588-27-6P 648876-60-2P
 740842-17-5P 740842-18-6P 740842-19-7P
 740842-20-0P 740842-21-1P 740842-23-3P
 740842-24-4P 740842-25-5P 740842-26-6P
 740842-28-8P 740843-01-0P 740843-02-1P
 740843-03-2P 740843-04-3P 740843-05-4P
 740843-07-6P 740843-10-1P 740843-13-4P
 740843-14-5P 740843-15-6P 740843-19-0P
 740843-20-3P 740843-21-4P 740843-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.)

RN 444587-84-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10773588



RN 444588-27-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648876-60-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-17-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-18-6 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-19-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6,7-dihydro-5H-benzocyclohepten-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-20-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-21-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-23-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-24-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-bromo-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-25-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-26-6 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,1-dioxido-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-28-8 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 740843-01-0 HCAPLUS

CN Acetamide, N-[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 740843-02-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-pyridinylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 740843-03-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(phenylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 740843-04-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(4-fluorophenyl)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 740843-05-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-thienylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 740843-07-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(3-furanylmethylene)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 740843-10-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740843-13-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzoxepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-14-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-15-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740843-19-0 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-20-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-21-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6,6-difluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740843-23-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10773588



IT 740842-32-4P 740842-33-5P 740842-34-6P
740842-35-7P 740842-37-9P 740842-39-1P
740842-45-9P 740842-46-0P 740842-47-1P
740842-48-2P 740842-49-3P 740842-53-9P
740842-54-0P 740842-55-1P 740842-56-2P
740842-58-4P 740842-59-5P 740842-60-8P
740842-61-9P 740842-65-3P 740842-67-5P
740842-68-6P 740842-70-0P 740842-90-4P
740842-92-6P 740842-94-8P 740842-96-0P
740842-99-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.)

RN 740842-32-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohept-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-33-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohept-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-34-6 HCAPLUS

Updated Search

10773588

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-35-7 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-37-9 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-39-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-45-9 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-46-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-47-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-48-2 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-49-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-53-9 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-54-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methanesulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-55-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-56-2 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-58-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-59-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-60-8 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-61-9 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-65-3 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[5S]-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 740842-67-5 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[5S]-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 740842-68-6 HCAPLUS


CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[5S]-2-oxo-3-(2,3,4,5-tetrahydro-1,1-dioxido-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]-

Updated Search

10773588

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-70-0 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[5S]-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-90-4 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-92-6 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(5R)-5-[[(methanesulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-94-8 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-96-0 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-99-3 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:675745 HCAPLUS

DOCUMENT NUMBER: 141:207196

TITLE: Preparation of tricyclic-substituted oxazolidinones and related compounds as antibacterial agents

INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Kim, Ji-Young; Choy, Allison Laura; Hagen, Susan Elizabeth; Boyer, Frederick Earl, Jr.

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 311 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069832	A2	20040819	WO 2004-IB237	20040127
WO 2004069832	A3	20041021		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,			

Updated Search

MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

CA 2515311	AA	20040819	CA 2004-2515311	20040127
EP 1594865	A2	20051116	EP 2004-705476	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007252	A	20060131	BR 2004-7252	20040127
JP 2006516991	T2	20060713	JP 2006-502379	20040127
US 2005288273	A1	20051229	US 2004-774241	20040206
PRIORITY APPLN. INFO.:			US 2003-445821P	P 20030207
			WO 2004-IB237	W 20040127
OTHER SOURCE(S): MARPAT 141:207196				
GI.				



AB Title compds. I [wherein A = O, NH, S; B = COR1, CSR1, heterocyclyl(carbonyl), heteroaryl(carbonyl); D = N, C, CH; E = C, N; F = CH, CH2; P = (un)substituted tri(hetero)cyclyl; R1 = H, (cyclo)alkyl(thio), (cyclo)alkoxy, (cycloalkyl)amino, (di)alkylamino; and pharmaceutically acceptable salts thereof] were prepared For example, (S)-N-[3-(6-dimethylaminomethylene-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-ylmethyl]acetamide was cyclized with NH₂NH₂•H₂O in EtOH to give the diazabenzazulene II (67%). The latter exhibited antibacterial activity against an assortment of Gram-neg. (MIC ranging from 2 µg/mL to >64 µg/mL), Gram-pos. (MIC ranging from 0.125 µg/mL to 0.5 µg/mL), and drug resistant (MIC ranging from 0.25 µg/mL to 16 µg/mL) organisms. Thus, I and their pharmaceutically acceptable compns. are useful as antibacterial agents.

IT 740842-23-3P 740842-24-4P 740842-46-0P,
(R)-Methanesulfonic acid [2-oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 740842-49-3P
740843-02-1P 740843-04-3P 740843-05-4P
741721-29-9P, N-[[(S)-3-(4-Fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
741721-36-8P, N-[[(S)-3-(1-Fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
741721-42-6P, N-[[(S)-3-(3-Fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
741721-48-2P, N-[[(S)-3-(1,4-Difluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
741721-57-3P, N-[[(S)-2-Oxo-3-[9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-3-yl]oxazolidin-5-yl]methyl]acetamide
741721-68-6P 741721-72-2P 741721-76-6P
741721-78-8P 741721-82-4P 741721-85-7P
741721-98-2P, [[(S)-2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]carbamic acid tert-butyl

10773588


ester 741722-00-9P 741723-35-3P, (R)-5-(Isoxazol-3-yloxymethyl)-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 741723-37-5P 741723-40-0P, (R)-3-(5-Oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-[[pyridin-2-yl]oxy]methyl]oxazolidin-2-one 741723-41-1P, 1-[[[(S)-2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]-1H-pyridin-2-one 741723-42-2P 741723-45-5P 741723-84-2P 741723-88-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antibacterial agent; preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)

RN 740842-23-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-24-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-bromo-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-46-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-49-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740843-02-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-pyridinylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 740843-04-3 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[6-[(4-fluorophenyl)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

Updated Search


10773588



RN 740843-05-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-thienylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741721-29-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-36-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(1-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-42-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-48-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(1,4-difluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-57-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-oxo-5H-cyclohepta[b]pyridin-3-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-68-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-1-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741721-72-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-3-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741721-76-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-1,4-difluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 741721-78-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[8-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-9-oxo-5H-cyclohepta[b]pyridin-3-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741721-82-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741721-85-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-fluoro-6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-98-2 HCAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 741722-00-9 HCAPLUS

CN Carbamic acid, [[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-35-3 HCAPLUS


CN 2-Oxazolidinone, 5-[(3-isoxazolyloxy)methyl]-3-(6,7,8,9-tetrahydro-5-oxo-

Updated Search

10773588

5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741723-37-5 HCAPLUS

CN 2-Oxazolidinone, 3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 741723-40-0 HCAPLUS

CN 2-Oxazolidinone, 5-[(2-pyridinyloxy)methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741723-41-1 HCAPLUS


CN 2(1H)-Pyridinone, 1-[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-

Updated Search

10773588

benzocyclohepten-2-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-42-2 HCAPLUS

CN 2-Oxazolidinone, 3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-5-[(2-pyridinyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-45-5 HCAPLUS

CN 2(1H)-Pyridinone, 1-[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




Updated Search

10773588

RN 741723-84-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(3-cyanophenyl)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-88-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(1,3-benzodioxol-5-ylmethylene)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 740842-19-7P, N-[[[(S)-3-(8,9-Dihydro-7H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl)methyl]acetamide 740843-03-2P
741721-86-8P, N-[[[(S)-3-(4-Fluoro-8,9-dihydro-7H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl)methyl]acetamide 741722-91-8P
741722-94-1P 741723-36-4P 741723-50-2P,
Cyclopentanecarboxylic acid N-[[[(S)-2-oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl)methyl]amide 741723-82-0P
741723-83-1P 741723-86-4P 741723-91-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)


RN 740842-19-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6,7-dihydro-5H-benzocyclohepten-3-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740843-03-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(phenylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741721-86-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(1-fluoro-6,7-dihydro-5H-benzocyclohepten-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741722-91-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(2-thiazolylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 741722-94-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(1-methyl-1H-pyrrol-2-yl)methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-36-4 HCAPLUS

CN 2-Oxazolidinone, 5-[(3-isoxazolyloxy)methyl]-3-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741723-50-2 HCAPLUS

CN Cyclopentanecarboxamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741723-82-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[[4-[3-(dimethylamino)propoxy]phenyl]methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-83-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[[4-(2-hydroxyethoxy)phenyl]methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-86-4 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[6-[[4-[2-(diethylamino)ethoxy]phenyl]methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10773588

Double bond geometry unknown.




RN 741723-91-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[[4-(methylsulfonyl)phenyl]methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 740842-17-5P, N-[[[(S)-2-Oxo-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
740842-18-6P, N-[[[(S)-2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
740842-20-0P, N-[[[(S)-2-Oxo-3-(7-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
740842-21-1P, N-[[[(S)-2-Oxo-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
740842-32-4P, (R)-5-Hydroxymethyl-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-33-5P, (R)-Methanesulfonic acid [2-oxo-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 740842-34-6P, (R)-5-Azidomethyl-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-35-7P, (S)-5-Aminomethyl-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-37-9P, N-(2,4-Dimethoxybenzyl)-N-[[[(S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide 740842-39-1P, N-[[[(S)-2-Oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide 740842-45-9P, (R)-5-Hydroxymethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-47-1P, (R)-5-Azidomethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-48-2P, (S)-5-Aminomethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-58-4P, (R)-5-Hydroxymethyl-3-(8-oxo-6,7,8,9-tetrahydro-5H-

Updated Search

benzocyclohepten-2-yl)oxazolidin-2-one 740842-59-5P,
 Methanesulfonic acid [(R)-2-oxo-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 740842-60-8P,
 (R)-5-Azidomethyl-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-61-9P, (S)-5-Aminomethyl-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-65-3P, N-(2,4-Dimethoxybenzyl)-N-[[[(S)-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide 740843-01-0P 741721-11-9P 741721-23-3P,
 (R)-5-Hydroxymethyl-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 741721-24-4P, (R)-5-Methanesulfonic acid [2-oxo-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 741721-25-5P, (R)-5-Azidomethyl-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 741721-65-3P
 741721-66-4P 741721-67-5P 741721-96-0P
 741722-39-4P 741722-43-0P 741722-44-1P
 741722-46-3P 741722-48-5P 741722-50-9P
 741722-52-1P 741722-54-3P 741722-57-6P
 741722-58-7P 741722-60-1P 741722-63-4P
 741722-64-5P 741722-67-8P 741722-68-9P
 741722-70-3P 741722-72-5P 741722-74-7P
 741722-76-9P 741722-79-2P 741722-80-5P
 741722-82-7P 741722-83-8P 741722-85-0P
 741722-87-2P 741722-93-0P 741723-33-1P
 741723-49-9P 741723-52-4P 741723-54-6P
 741723-56-8P 741723-58-0P 741723-60-4P
 741723-62-6P 741723-64-8P 741723-66-0P
 741723-68-2P 741723-70-6P 741723-72-8P
 741723-73-9P 741723-74-0P 741723-75-1P
 742101-55-9P 742101-56-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)

RN 740842-17-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-18-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10773588



RN 740842-20-0 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-21-1 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-32-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-33-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-34-6 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-35-7 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-37-9 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-39-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-45-9 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-47-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-48-2 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-58-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-59-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10773588



RN 740842-60-8 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-61-9 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-65-3 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740843-01-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741721-11-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-bromo-6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-23-3 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 741721-24-4 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methanesulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-25-5 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-65-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[9-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-3-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-66-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-9-[(tetrahydro-2H-pyran-2-yl)oxy]-5H-cyclohepta[b]pyridin-3-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-67-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-hydroxy-5H-cyclohepta[b]pyridin-3-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741721-96-0 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[5-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-6-

Updated Search

10773588

oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741722-39-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[bis(methylthio)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-43-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(trifluoroacetyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-44-1 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-benzoyl-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-46-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-acetyl-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-48-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[4-(trifluoromethoxy)benzoyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-50-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(4-cyanobenzoyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-52-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-thiazolylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry..



RN 741722-54-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(5-isoxazolylcarbonyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-57-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(3-furanylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-58-7 HCAPLUS

CN 3-Furancarboxamide, N-[[[(5S)-3-[6-(3-furanylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-60-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-63-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-64-5 HCAPLUS

CN 3-Isioxazolecarboxamide, 5-methyl-N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-67-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-68-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741722-70-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[(2-phenyl-4-thiazolyl)carbonyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-72-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[(5-phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-74-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-76-9 HCAPLUS

CN Carbamic acid, [[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(5-isoxazolylcarbonyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-79-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(2-benzofuranylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-80-5 HCAPLUS

CN 2-Benzofurancarboxamide, N-[[[(5S)-3-[6-(2-benzofuranylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-82-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-83-8 HCAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[[[(5S)-3-[6-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-85-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-fluoro-6,7,8,9-tetrahydro-6-(5-isoxazolylcarbonyl)-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-87-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(2-benzothiazolylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-93-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(4-hydroxyphenyl)methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741723-33-1 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[(phenylmethoxy)acetyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-49-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(cyclopentylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-52-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(2-methyl-1-oxopropyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741723-54-6 HCAPLUS

CN Propanamide, 2-methyl-N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(2-methyl-1-oxopropyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry..



RN 741723-56-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(1-oxopropyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry..




RN 741723-58-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(1-oxobutyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741723-60-4 HCAPLUS

CN Butanamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(1-oxobutyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-62-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(2-thienylacetyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741723-64-8 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[4-fluoro-6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588

oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-66-0 HCAPLUS

CN 3-Isoxazolecarboxamide, N-[[[(5S)-3-[4-fluoro-6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-5-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-68-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741723-70-6 HCAPLUS


CN 1H-Pyrazole-3-carboxamide, N-[[[(5S)-3-[6-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-

Updated Search

10773588

oxo-5-oxazolidinyl)methyl]-1,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-72-8 HCAPLUS

Acetamide, N-[[[(5S)-3-[4-fluoro-6-(2-furanylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-73-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-oxo-5-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741723-74-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-oxo-5-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741723-75-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-(5-isoxazolylcarbonyl)-6-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 742101-55-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(4-fluorobenzoyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 742101-56-0 HCAPLUS

CN Acetamide, N-[[[(5R)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 741721-99-3, (S)-5-Aminomethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)


RN 741721-99-3 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, monohydrochloride, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10773588



● HCl

=> d his

(FILE 'HOME' ENTERED AT 15:09:36 ON 26 SEP 2006)

FILE 'REGISTRY' ENTERED AT 15:09:47 ON 26 SEP 2006

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 202 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:10:56 ON 26 SEP 2006

FILE 'REGISTRY' ENTERED AT 15:10:59 ON 26 SEP 2006

L4 STRUCTURE UPLOADED

L5 4 S L4

L6 202 S L4 FULL

FILE 'HCAPLUS' ENTERED AT 15:14:04 ON 26 SEP 2006

L7 7 S L6

L8 3 S L7 AND CHUPAK, L?/AU

=> s l7 not l8

L9 4 L7 NOT L8

=> s l9 and boyer, f?/au

157 BOYER, F?/AU

L10 0 L9 AND BOYER, F?/AU

=> s l9 and hagen, s?/au

344 HAGEN, S?/AU

L11 1 L9 AND HAGEN, S?/AU

=> d l11, ibib abs hitstr, 1

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:260064 HCAPLUS

DOCUMENT NUMBER: 142:336347

TITLE: Preparation of substituted quinolones and derivatives thereof as antibacterial agents

INVENTOR(S): Hagen, Susan Elizabeth; Josyula, Vara Prasad Venkata Nagendra



PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

Updated Search

10773588

SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026161	A1	20050324	WO 2004-IB2894	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005070523	A1	20050331	US 2004-931400	20040901
CA 2539160	AA	20050324	CA 2004-2539160	20040906
EP 1670793	A1	20060621	EP 2004-769293	20040906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-503415P	P 20030916
			WO 2004-IB2894	W 20040906
OTHER SOURCE(S):	MARPAT 142:336347			
GI				



AB Title compds. I [Z2 = aminocarbonyl, carbonylamino, CN; either D = N, E = C, F = CH or D = CH, E = N, F = CH₂ if --- is absent; J, K, Q = (un)substituted alkyl, N with provisions; n = 0-2; at least one of W, X, Y = NP; P = substituted quinolone] are prepared For instance, II is prepared from 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid boron difluoride chelate and N-[2-oxo-3-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)oxazolidin-5-ylmethyl]acetamide to give an intermediate borate ester which is converted to the final product upon treatment with Et₃N, water at reflux for 18 h. II has MIC 1 µg/mL against *E. Faecalis* and 0.06 µg/mL against *S. aureus*. I are useful for the treatment of bacterial infections.


IT 848194-15-0P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-8-methoxy-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-17-2P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-18-3P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid 848194-19-4P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-20-7P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-21-8P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-22-9P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-24-1P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinolones and derivs. thereof as antibacterial agents)

RN 848194-15-0 HCAPLUS


CN 3-Quinolonecarboxylic acid, 7-[7-[5-[(acetyl amino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-5-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 848194-17-2 HCAPLUS


10773588

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-18-3 HCAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 848194-19-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-20-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Updated Search

10773588




RN 848194-21-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 848194-22-9 HCAPLUS


CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-24-1 HCAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10773588



IT 848194-16-1, N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxazolidin-5-ylmethyl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted quinolones and derivs. thereof as antibacterial agents)
RN 848194-16-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:09:36 ON 26 SEP 2006)

FILE 'REGISTRY' ENTERED AT 15:09:47 ON 26 SEP 2006

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 202 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:10:56 ON 26 SEP 2006

FILE 'REGISTRY' ENTERED AT 15:10:59 ON 26 SEP 2006

L4 STRUCTURE UPLOADED

L5 4 S L4

L6 202 S L4 FULL

FILE 'HCAPLUS' ENTERED AT 15:14:04 ON 26 SEP 2006

L7 7 S L6

L8 3 S L7 AND CHUPAK, L?/AU

L9 4 S L7 NOT L8

L10 0 S L9 AND BOYER, F?/AU

L11 1 S L9 AND HAGEN, S?/AU

=> s 19 not 111

Updated Search

10773588

L12 3 L9 NOT L11

=> s l12 and kaneko, t?/au
 6486 KANEKO, T?/AU

L13 0 L12 AND KANEKO, T?/AU

=> s l12 and lall, m?/au
 15 LALL, M?/AU

L14 0 L12 AND LALL, M?/AU


=> s l12 and pattersson, m?/au
 0 PATTERSSON, M?/AU

L15 0 L12 AND PATTERSSON, M?/AU

=> s l12 and prasad, j?/au
 748 PRASAD, J?/AU

L16 0 L12 AND PRASAD, J?/AU

=>



chain nodes :

19 20 22 23 24 25 26 27 37 38 39

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18

chain bonds :

6-18 14-19 16-20 23-24 37-38

ring bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 7-8 8-9 9-10 10-11 14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 6-18 7-8 8-9 9-10 10-11 14-15 14-18 14-19 15-16 16-17
16-20 17-18 23-24 37-38

isolated ring systems :

containing 1 : 14 :

G1:C,N

G2:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS20:CLASS22:CLASS23:CLASS24:CLASS25:CLASS26:CLASS
27:CLASS37:CLASS38:CLASS39:CLASS

19 20 22 23 24 25 26 27

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18

6-18 14-19 16-20 23-24


1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 7-8 8-9 9-10 10-11 14-15 14-18 15-16 16-17 17-18

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 6-18 7-8 8-9 9-10 10-11 14-15 14-18 14-19 15-16 16-17
16-20 17-18 23-24

containing 1 : 14 :

G2:[*1],[*2],[*3],[*4],[*5]

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS20:CLASS22:CLASS23:CLASS24:CLASS25:CLASS26:CLASS
27:CLASS



chain nodes :

19 20 22 23 24 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18

chain bonds :

6-18 14-19 16-20 23-24

ring bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 7-8 8-9 9-10 10-11 14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 6-18 7-8 8-9 9-10 10-11 14-15 14-18 14-19 15-16 16-17
16-20 17-18 23-24

isolated ring systems :

containing 1 : 14 :

G1:C,N

G2:[*1],[*2],[*3],[*4],[*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS

10773588

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

Updated Search

10773588

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:02:53 ON 26 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'REGISTRY' ENTERED AT 17:04:37 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\6767e.str

L1 STRUCTURE UPLOADED

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\6767a.str

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2 STR.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 12

SAMPLE SEARCH INITIATED 17:06:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 12309 TO ITERATE

Updated Search

10773588

16.2% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 239533 TO 252827
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L2

=> s l2 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 17:06:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 246888 TO ITERATE

100.0% PROCESSED 246888 ITERATIONS
SEARCH TIME: 00.00.01

163 ANSWERS

L4 163 SEA SSS FUL L2

=> d his

(FILE 'HOME' ENTERED AT 17:02:53 ON 26 SEP 2006)

FILE 'REGISTRY' ENTERED AT 17:04:37 ON 26 SEP 2006

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 0 S L2
L4 163 S L2 FULL

=> file hcaplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
167.82	168.45

FILE 'HCAPLUS' ENTERED AT 17:06:37 ON 26 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

Updated Search

10773588

substance identification.

=> s l4

L5 7 L4

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.53

170.98

FILE 'REGISTRY' ENTERED AT 17:06:52 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\6767e.str

L6 STRUCTURE UPLOADED

=> d l6

L6 HAS NO ANSWERS

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l6

SAMPLE SEARCH INITIATED 17:08:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4265 TO ITERATE

46.9% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

Updated Search

10773588

PROJECTED ITERATIONS: 81384 TO 89216
PROJECTED ANSWERS: 4 TO 345

L7 4 SEA SSS SAM L6

=> s l6 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 17:08:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 87152 TO ITERATE

100.0% PROCESSED 87152 ITERATIONS 202 ANSWERS
SEARCH TIME: 00.00.01

L8 202 SEA SSS FUL L6

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	338.36

FILE 'HCAPLUS' ENTERED AT 17:08:15 ON 26 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8

L9 7 L8

=> d his

(FILE 'HOME' ENTERED AT 17:02:53 ON 26 SEP 2006)

FILE 'REGISTRY' ENTERED AT 17:04:37 ON 26 SEP 2006

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 0 S L2
L4 163 S L2 FULL

FILE 'HCAPLUS' ENTERED AT 17:06:37 ON 26 SEP 2006

Updated Search

10773588

L5 7 S L4

FILE 'REGISTRY' ENTERED AT 17:06:52 ON 26 SEP 2006

L6 STRUCTURE UPLOADED

L7 4 S L6


L8 202 S L6 FULL

FILE 'HCAPLUS' ENTERED AT 17:08:15 ON 26 SEP 2006

L9 7 S L8

=> s l5 not l9

L10 0 L5 NOT L9



chain nodes :

19 20 22 23 24 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18

chain bonds :

6-18 14-19 16-20 23-24

ring bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 7-8 8-9 9-10 10-11 14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 6-18 7-8 8-9 9-10 10-11 14-15 14-18 14-19 15-16 16-17
16-20 17-18 23-24

isolated ring systems :



containing 1 : 14 :

G1:C,N

G2:[*1],[*2],[*3],[*4],[*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:CLAS20:CLAS22:CLAS23:CLAS24:CLAS25:CLAS26:CLASS
27:CLASS



chain nodes :

19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18

chain bonds :

6-18 14-19 16-20

ring bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 7-8 8-9 9-10 10-11 14-15 14-18 15-16 16-17 17-18

exact/norm bonds :

1-2 1-6 2-3 2-11 3-4 3-7 4-5 5-6 6-18 7-8 8-9 9-10 10-11 14-15 14-18 14-19 15-16 16-17
16-20 17-18

isolated ring systems :

containing 1 : 14 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 14:Atom
15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS

10773588

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

Updated Search

10773588

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:27:05 ON 26 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:27:11 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\4545.str

L1 STRUCTURE UPLOADED


=> d l1

L1 HAS NO ANSWERS

L1 STR

Updated Search

10773588



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:30:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 14:30:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 26 TO ITERATE

100.0% PROCESSED 26 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\6767e.str

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

Updated Search

10773588

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 14:34:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4265 TO ITERATE

46.9% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 81384 TO 89216

PROJECTED ANSWERS: 4 TO 345

L5 4 SEA SSS SAM L4

=> s l4 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 14:34:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 87152 TO ITERATE

100.0% PROCESSED 87152 ITERATIONS
SEARCH TIME: 00.00.01

202 ANSWERS

L6 202 SEA SSS FUL L4

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

338.28

338.49

FILE 'HCAPLUS' ENTERED AT 14:34:11 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14

FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Updated Search

10773588

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16

L7 7 L6

=> d 17, ibib abs hitstr, 1-7

L7 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1021741 HCAPLUS

DOCUMENT NUMBER: 143:326234

TITLE: Preparation of benzazepine derivatives as antagonists of histamine H1 and H3

INVENTOR(S): Bamford, Mark James; Heightman, Thomas Daniel; Wilson, David Matthew; Witherington, Jason

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087746	A1	20050922	WO 2005-GB939	20050310
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2004-5628 A 20040312

OTHER SOURCE(S): MARPAT 143:326234

GI

10773588



AB Title compds. I [R1 = (un)substituted cycloalkyl; R2 = aryl, heteroaryl, heterocycle, etc.; R3 = H, alkoxy, CN, etc.; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of histamine H1 and H3. Thus, e.g., II was prepared by coupling of 3-cyclobutyl-7-(1-piperazinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (preparation given) with 3-bromobenzonitrile. The activity of I was evaluated in the histamine H3 functional antagonist assay and selected compds. of the invention displayed a pKb in the range of >6.5 and >9.0. I as antagonists of histamine H1 and H3 should prove useful in the treatment of neurol. diseases. Pharmaceutical compns. comprising I are disclosed.

IT 865111-69-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 865111-69-9 HCAPLUS

CN 2-Oxazolidinone, 3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

10773588

IT 865110-81-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 865110-81-2 HCAPLUS

CN Benzonitrile, 4-[[[(5R)-3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 865111-76-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 865111-76-8 HCAPLUS

CN 2-Oxazolidinone, 3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-[[[(methylsulfonyl)oxy]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:260064 HCAPLUS

DOCUMENT NUMBER: 142:336347

TITLE: Preparation of substituted quinolones and derivatives thereof as antibacterial agents

INVENTOR(S): Hagen, Susan Elizabeth; Josyula, Vara Prasad Venkata Nagendra

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 104 pp.



CODEN: PIXXD2

Updated Search

10773588

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026161	A1	20050324	WO 2004-IB2894	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005070523	A1	20050331	US 2004-931400	20040901
CA 2539160	AA	20050324	CA 2004-2539160	20040906
EP 1670793	A1	20060621	EP 2004-769293	20040906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-503415P	P 20030916
			WO 2004-IB2894	W 20040906
OTHER SOURCE(S):	MARPAT 142:336347			
GI				



AB Title compds. I [Z₂ = aminocarbonyl, carbonylamino, CN; either D = N, E =

Updated Search

C, F = CH or D = CH, E = N, F = CH₂ if --- is absent; J, K, Q = (un)substituted alkyl, N with provisions; n = 0-2; at least one of W, X, Y = NP; P = substituted quinolone] are prepared For instance, II is prepared from 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid boron difluoride chelate and N-[2-oxo-3-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)oxazolidin-5-ylmethyl]acetamide to give an intermediate borate ester which is converted to the final product upon treatment with Et₃N, water at reflux for 18 h. II has MIC 1 µg/mL against E. Faecalis and 0.06 µg/mL against S. aureus. I are useful for the treatment of bacterial infections.


IT 848194-15-0P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-8-methoxy-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-17-2P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-18-3P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid 848194-19-4P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-20-7P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-21-8P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-22-9P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 848194-24-1P, 7-[7-[5-(Acetylaminomethyl)-2-oxooxazolidin-3-yl]-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinolones and derivs. thereof as antibacterial agents)

RN 848194-15-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetyl amino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-5-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-17-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetyl amino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-


10773588

fluoro-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-18-3 HCAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 848194-19-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-20-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Updated Search

10773588




RN 848194-21-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 848194-22-9 HCAPLUS


CN 3-Quinolinecarboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 848194-24-1 HCAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-[7-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10773588



IT 848194-16-1, N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxazolidin-5-ylmethyl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted quinolones and derivs. thereof as antibacterial agents)
RN 848194-16-1 HCAPLUS
CN Acetamide, N-[[2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:681569 HCAPLUS
DOCUMENT NUMBER: 141:207197
TITLE: Preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.
INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Jiao, Wenhua
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069245	A1	20040819	WO 2004-IB231	20040127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,			

Updated Search




10773588

GQ, GW, ML, MR, NE, SN, TD, TG

CA 2514241	AA	20040819	CA 2004-2514241	20040127
EP 1594495	A1	20051116	EP 2004-705475	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007335	A	20060110	BR 2004-7335	20040127
JP 2006516990	T2	20060713	JP 2006-502378	20040127
US 2005277630	A1	20051215	US 2004-772860	20040206
PRIORITY APPLN. INFO.:			US 2003-445909P	P 20030207
			WO 2004-IB231	W 20040127

OTHER SOURCE(S): MARPAT 141:207197

GI



AB Title compds. I [A = O, NH, S; B = COR₁, CSR₁, heterocyclo, etc.; R₁ = H, alkyl, cycloalkyl, etc.; either D is N, E is C, and F = CH when "----" is a bond, or D = CH, E = N, and F = CH₂ when "----" is absent (sic); P = tricyclic ring with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of hydrazine and dimethylaminomethylene II afforded oxazolidinone III in 60% yield. In H. influenzae (HI3542) min. inhibitory concentration (MIC) assays, 8-examples of compds. I exhibited MIC values ranging from 4->64 µg/mL, e.g., the MIC value of oxazolidinone III was 8 µg/mL. Compds. I are claimed useful for the treatment of bacterial infections.

IT 741253-96-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 741253-96-3 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[2-[(dimethylamino)methylene]-1,2,4,5-tetrahydro-3,3-dioxido-1-oxo-3-benzothiepin-7-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10773588

Double bond geometry unknown.



IT 740842-28-8P 741253-88-3P 741253-89-4P

741253-92-9P 741254-17-1P 741254-18-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 740842-28-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 741253-88-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-1-oxo-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741253-89-4 HCAPLUS


CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-1-oxo-3-

Updated Search

10773588

benzothiepin-7-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741253-92-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-17-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(4-pyridinylmethylene)-1-benzoxepin-8-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 741254-18-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(dimethylamino)methylene]-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588

Absolute stereochemistry.
Double bond geometry unknown.



IT 741254-27-3P 741254-38-6P 741254-39-7P
741254-40-0P 741254-41-1P 741254-43-3P
741254-55-7P 741254-56-8P 741254-57-9P
741254-58-0P 741254-60-4P 741254-61-5P
741254-62-6P 741254-63-7P 741254-64-8P
741254-65-9P 741254-66-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted tricyclic oxazolidinones as antibacterial agents.)

RN 741254-27-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-bromo-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-38-6 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




Updated Search

10773588

RN 741254-39-7 HCAPLUS

CN Butanoic acid, [(5R)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-40-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-41-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-43-3 HCAPLUS

Updated Search

10773588

CN Butanoic acid, [(5R)-2-oxo-3-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-8-yl)-5-oxazolidinyl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-55-7 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-56-8 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-57-9 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(1,3,4,5-tetrahydro-5-oxo-2-benzothiepin-8-yl)-, (5R)- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 741254-58-0 HCAPLUS

CN 1-Benzoxepin-4-carbodithioic acid, 8-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,3,4,5-tetrahydro-5-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-60-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(4-fluorobenzoyl)-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-61-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(4-pyridinylcarbonyl)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 741254-62-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-benzoyl-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-63-7 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-4-(5-isoxazolylcarbonyl)-5-oxo-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741254-64-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-5-oxo-4-(1-oxopropyl)-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 741254-65-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-4-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-1-benzoxepin-8-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741254-66-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:681568 HCAPLUS

DOCUMENT NUMBER: 141:190784


TITLE: Preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.

Updated Search


10773588

INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara
Prasad Venkata Nagendra; Pettersson, Martin Youngjin;
Lall, Manjinder Singh; Hagen, Susan Elizabeth; Boyer,
Frederick Earl, Jr.
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069244	A1	20040819	WO 2004-IB209	20040127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515269	AA	20040819	CA 2004-2515269	20040127
EP 1594494	A1	20051116	EP 2004-705472	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007304	A	20060110	BR 2004-7304	20040127
JP 2006516989	T2	20060713	JP 2006-502372	20040127
US 2004224939	A1	20041111	US 2004-773588	20040205
PRIORITY APPLN. INFO.:			US 2003-445957P	P 20030207
			WO 2004-IB209	W 20040127
OTHER SOURCE(S):		MARPAT 141:190784		
GI				



I



II



III

AB Title compds. I [A = O, NH, S; B = COR1, CSR1, heterocyclo, etc.; R1 = H, alkyl, cycloalkyl, etc.; either D is N, E is C, and F = CH when "----" is a bond, or D = CH, E = N, and F = CH2 when "----" is absent (sic); P = bicyclic ring, e.g., benzo[b]cycloheptanones, homochromanones, homothiochromanones, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, CrO3/Ac2O mediated oxidation of benzocycloheptane II, e.g., prepared from 1-benzouberone in 5-steps, afforded oxazolidinone III in 14% yield. In H. influenzae (HI3542) min. inhibitory concentration (MIC) assays, 15-examples of compds. I exhibited MIC values ranging from 2->64 µg/mL, e.g., the MIC value of oxazolidinone III was 8 µg/mL. Compds. I are claimed useful for the treatment of bacterial infections.

IT 444587-84-2P 444588-27-6P 648876-60-2P
 740842-17-5P 740842-18-6P 740842-19-7P
 740842-20-0P 740842-21-1P 740842-23-3P
 740842-24-4P 740842-25-5P 740842-26-6P
 740842-28-8P 740843-01-0P 740843-02-1P
 740843-03-2P 740843-04-3P 740843-05-4P
 740843-07-6P 740843-10-1P 740843-13-4P
 740843-14-5P 740843-15-6P 740843-19-0P
 740843-20-3P 740843-21-4P 740843-23-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.)

RN 444587-84-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444588-27-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10773588

RN 648876-60-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-17-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-18-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-19-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6,7-dihydro-5H-benzocyclohepten-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-20-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-21-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-23-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-24-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-bromo-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-25-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-26-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,1-dioxido-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-28-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry. Rotation (-).



RN 740843-01-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 740843-02-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-pyridinylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 740843-03-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(phenylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

Double bond geometry unknown.



CN Acetamide, N-[[[(5S)-3-[6-[(4-fluorophenyl)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

CC(=O)N[C@@H]1OC(=O)N1c2ccccc2C3=C(C(=O)O)C(=C(C=C3)C=Cc4ccc(F)cc4)C5=CC=CC=C5

CN Acetamide, N-[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-thienylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


CC(=O)N[C@@H]1SC(=O)N1c2ccc3c(c2)C(=O)C=Cc4ccsc4

CN Acetamide, N-[[[(5S)-3-[6-(3-furanylmethylene)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohept-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Updated Search


10773588

Absolute stereochemistry.
Double bond geometry unknown.




RN 740843-10-1 HCAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 740843-13-4 HCAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzoxepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740843-14-5 HCAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740843-15-6 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-19-0 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(1,3,4,5-tetrahydro-2-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-20-3 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740843-21-4 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-3-(6,6-difluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740843-23-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 740842-32-4P 740842-33-5P 740842-34-6P
740842-35-7P 740842-37-9P 740842-39-1P
740842-45-9P 740842-46-0P 740842-47-1P
740842-48-2P 740842-49-3P 740842-53-9P
740842-54-0P 740842-55-1P 740842-56-2P
740842-58-4P 740842-59-5P 740842-60-8P
740842-61-9P 740842-65-3P 740842-67-5P
740842-68-6P 740842-70-0P 740842-90-4P
740842-92-6P 740842-94-8P 740842-96-0P
740842-99-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted bicyclic oxazolidinones as antibacterial agents.)


RN 740842-32-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-33-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[(methanesulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-34-6 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-35-7 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-37-9 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-39-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-45-9 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-46-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 740842-47-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-48-2 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-49-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-53-9 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-54-0 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-55-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-56-2 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-58-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-59-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-], (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-60-8 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-61-9 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-65-3 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-67-5 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 740842-68-6 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[5S]-2-oxo-3-(2,3,4,5-tetrahydro-1,1-dioxido-5-oxo-1-benzothiepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-70-0 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[5S]-2-oxo-3-(2,3,4,5-tetrahydro-5-oxo-1-benzoxepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-90-4 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-92-6 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(5R)-5-[[methylsulfonyl]oxy]methyl]-2-oxo-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 740842-94-8 HCAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Updated Search

10773588

INDEX NAME)


Absolute stereochemistry.



RN 740842-96-0 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-99-3 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:675745 HCAPLUS

DOCUMENT NUMBER: 141:207196

TITLE: Preparation of tricyclic-substituted oxazolidinones

Updated Search

10773588

and related compounds as antibacterial agents

INVENTOR(S): Chupak, Louis Stanley; Kaneko, Takushi; Josyula, Vara Prasad Venkata Nagendra; Kim, Ji-Young; Choy, Allison Laura; Hagen, Susan Elizabeth; Boyer, Frederick Earl, Jr.

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 311 pp.
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069832	A2	20040819	WO 2004-IB237	20040127
WO 2004069832	A3	20041021		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2515311	AA	20040819	CA 2004-2515311	20040127
EP 1594865	A2	20051116	EP 2004-705476	20040127
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007252	A	20060131	BR 2004-7252	20040127
JP 2006516991	T2	20060713	JP 2006-502379	20040127
US 2005288273	A1	20051229	US 2004-774241	20040206
PRIORITY APPLN. INFO.:			US 2003-445821P	P 20030207
			WO 2004-IB237	W 20040127
OTHER SOURCE(S):	MARPAT 141:207196			
GI				




AB Title compds. I [wherein A = O, NH, S; B = COR1, CSR1, heterocyclyl(carbonyl), heteroaryl(carbonyl); D = N, C, CH; E = C, N; F = CH, CH2; P = (un)substituted tri(hetero)cyclyl; R1 = H, (cyclo)alkyl(thio), (cyclo)alkoxy, (cycloalkyl)amino, (di)alkylamino; and pharmaceutically acceptable salts thereof] were prepared. For example, (S)-N-[3-(6-dimethylaminomethylene-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-ylmethyl]acetamide was cyclized with NH2NH2•H2O in EtOH to give the diazabenzocycloheptene II (67%). The

Updated Search

latter exhibited antibacterial activity against an assortment of Gram-neg. (MIC ranging from 2 µg/mL to >64 µg/mL), Gram-pos. (MIC ranging from 0.125 µg/mL to 0.5 µg/mL), and drug resistant (MIC ranging from 0.25 µg/mL to 16 µg/mL) organisms. Thus, I and their pharmaceutically acceptable compns. are useful as antibacterial agents.

- IT 740842-23-3P 740842-24-4P 740842-46-0P,
 (R)-Methanesulfonic acid [2-oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 740842-49-3P
 740843-02-1P 740843-04-3P 740843-05-4P
 741721-29-9P, N-[[[(S)-3-(4-Fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
 741721-36-8P, N-[[[(S)-3-(1-Fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
 741721-42-6P, N-[[[(S)-3-(3-Fluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
 741721-48-2P, N-[[[(S)-3-(1,4-Difluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
 741721-57-3P, N-[[[(S)-2-Oxo-3-[9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-3-yl]oxazolidin-5-yl]methyl]acetamide
 741721-68-6P 741721-72-2P 741721-76-6P
 741721-78-8P 741721-82-4P 741721-85-7P
 741721-98-2P, [[[(S)-2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]carbamic acid tert-butyl ester 741722-00-9P 741723-35-3P, (R)-5-(Isoxazol-3-yl)oxymethyl)-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 741723-37-5P 741723-40-0P,
 (R)-3-(5-Oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-[[[(pyridin-2-yl)oxy]methyl]oxazolidin-2-one 741723-41-1P,
 1-[[[(S)-2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]-1H-pyridin-2-one 741723-42-2P
 741723-45-5P 741723-84-2P 741723-88-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (antibacterial agent; preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)
 RN 740842-23-3 HCAPLUS
 CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



- RN 740842-24-4 HCAPLUS
 CN Acetamide, N-[[[(5S)-3-(6-bromo-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Updated Search

Absolute stereochemistry.




CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Acetamide, N-[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-pyridinylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 740843-04-3 HCAPLUS.

CN Acetamide, N-[[[(5S)-3-[6-[(4-fluorophenyl)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 740843-05-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-thienylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741721-29-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-36-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(1-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-42-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-48-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(1,4-difluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-57-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-oxo-5H-cyclohepta[b]pyridin-3-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-68-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-1-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 741721-72-2 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-3-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

Updated Search


10773588



RN 741721-76-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-1,4-difluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741721-78-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[8-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-9-oxo-5H-cyclohepta[b]pyridin-3-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741721-82-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 741721-85-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(4-fluoro-6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-98-2 HCAPLUS

CN Carbamic acid, [[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741722-00-9 HCAPLUS

CN Carbamic acid, [[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Updated Search


10773588

Absolute stereochemistry.
Double bond geometry unknown.




RN 741723-35-3 HCAPLUS
CN 2-Oxazolidinone, 5-[(3-isoxazolyloxy)methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741723-37-5 HCAPLUS
CN 2-Oxazolidinone, 3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-5-[(3-isoxazolyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741723-40-0 HCAPLUS
CN 2-Oxazolidinone, 5-[(2-pyridinyloxy)methyl]-3-(6,7,8,9-tetrahydro-5-oxo-5H-

Updated Search

10773588

benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-41-1 HCAPLUS

CN 2(1H)-Pyridinone, 1-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741723-42-2 HCAPLUS

CN 2-Oxazolidinone, 3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-5-[(2-pyridinyloxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 741723-45-5 HCAPLUS


CN 2(1H)-Pyridinone, 1-[[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-

Updated Search

10773588

tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-84-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(3-cyanophenyl)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



'RN 741723-88-6 HCAPLUS

CN Acetamide, N-[[(5S)-3-[6-(1,3-benzodioxol-5-ylmethylene)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




Updated Search

10773588


IT 740842-19-7P, N-[[[(S)-3-(8,9-Dihydro-7H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide 740843-03-2P
741721-86-8P, N-[[[(S)-3-(4-Fluoro-8,9-dihydro-7H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide 741722-91-8P
741722-94-1P 741723-36-4P 741723-50-2P,
Cyclopentanecarboxylic acid N-[[[(S)-2-oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]amide 741723-82-0P
741723-83-1P 741723-86-4P 741723-91-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)
RN 740842-19-7 HCAPLUS
CN Acetamide, N-[[[(5S)-3-(6,7-dihydro-5H-benzocyclohepten-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 740843-03-2 HCAPLUS
CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(phenylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741721-86-8 HCAPLUS
CN Acetamide, N-[[[(5S)-3-(1-fluoro-6,7-dihydro-5H-benzocyclohepten-3-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741722-91-8 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(2-thiazolylmethylene)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741722-94-1 HCAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(1-methyl-1H-pyrrol-2-yl)methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741723-36-4 HCAPLUS

CN 2-Oxazolidinone, 5-[(3-isoxazolyloxy)methyl]-3-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741723-50-2 HCAPLUS

CN Cyclopentanecarboxamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-82-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[4-[3-(dimethylamino)propoxy]phenyl]methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 741723-83-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[4-(2-hydroxyethoxy)phenyl]methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Updated Search


10773588



RN 741723-86-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[[4-[2-(diethylamino)ethoxy]phenyl]methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-91-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[[4-(methylsulfonyl)phenyl]methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 740842-17-5P, N-[[[(S)-2-Oxo-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
740842-18-6P, N-[[[(S)-2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
740842-20-0P, N-[[[(S)-2-Oxo-3-(7-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide

Updated Search

740842-21-1P, N-[[[(S)-2-Oxo-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
 740842-32-4P, (R)-5-Hydroxymethyl-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-33-5P,
 (R)-Methanesulfonic acid [2-oxo-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 740842-34-6P,
 (R)-5-Azidomethyl-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-35-7P, (S)-5-Aminomethyl-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one
 740842-37-9P, N-(2,4-Dimethoxybenzyl)-N-[[[(S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
 740842-39-1P, N-[[[(S)-2-Oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl]acetamide
 740842-45-9P, (R)-5-Hydroxymethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-47-1P,
 (R)-5-Azidomethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-48-2P, (S)-5-Aminomethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one
 740842-58-4P, (R)-5-Hydroxymethyl-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-59-5P,
 Methanesulfonic acid [(R)-2-oxo-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 740842-60-8P,
 (R)-5-Azidomethyl-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 740842-61-9P, (S)-5-Aminomethyl-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one
 740842-65-3P, N-(2,4-Dimethoxybenzyl)-N-[[[(S)-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxooxazolidin-5-yl]methyl]acetamide
 740843-01-0P 741721-11-9P 741721-23-3P,
 (R)-5-Hydroxymethyl-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 741721-24-4P, (R)-5-Methanesulfonic acid
 [2-oxo-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-5-yl]methyl ester 741721-25-5P, (R)-5-Azidomethyl-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one 741721-65-3P
 741721-66-4P 741721-67-5P 741721-96-0P
 741722-39-4P 741722-43-0P 741722-44-1P
 741722-46-3P 741722-48-5P 741722-50-9P
 741722-52-1P 741722-54-3P 741722-57-6P
 741722-58-7P 741722-60-1P 741722-63-4P
 741722-64-5P 741722-67-8P 741722-68-9P
 741722-70-3P 741722-72-5P 741722-74-7P
 741722-76-9P 741722-79-2P 741722-80-5P
 741722-82-7P 741722-83-8P 741722-85-0P
 741722-87-2P 741722-93-0P 741723-33-1P
 741723-49-9P 741723-52-4P 741723-54-6P
 741723-56-8P 741723-58-0P 741723-60-4P
 741723-62-6P 741723-64-8P 741723-66-0P
 741723-68-2P 741723-70-6P 741723-72-8P
 741723-73-9P 741723-74-0P 741723-75-1P
 742101-55-9P 742101-56-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)


RN 740842-17-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-18-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-20-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-21-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-32-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-33-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-34-6 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-35-7 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-9-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-37-9 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-39-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-45-9 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-47-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-48-2 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 740842-58-4 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 740842-59-5 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methanesulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-60-8 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 740842-61-9 HCAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-8-oxo-5H-benzocyclohepten-2-yl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 740842-65-3 HCAPLUS

CN Acetamide, N-[(2,4-dimethoxyphenyl)methyl]-N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 740843-01-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 741721-11-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-bromo-6,7,8,9-tetrahydro-7-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-23-3 HCAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-24-4 HCAPLUS

CN 2-Oxazolidinone, 5-[[[(methylsulfonyl)oxy]methyl]-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-25-5 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-(6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741721-65-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[9-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-3-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741721-66-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-9-[(tetrahydro-2H-pyran-2-yl)oxy]-5H-cyclohepta[b]pyridin-3-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-67-5 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-2-oxo-3-(6,7,8,9-tetrahydro-9-hydroxy-5H-cyclohepta[b]pyridin-3-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741721-96-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[5-[(dimethylamino)methylene]-6,7,8,9-tetrahydro-6-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 741722-39-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[bis(methylthio)methylene]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741722-43-0 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(trifluoroacetyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-44-1 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-benzoyl-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-46-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(6-acetyl-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-48-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[4-(trifluoromethoxy)benzoyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-50-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(4-cyanobenzoyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-52-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-thiazolylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-54-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(5-isoxazolylcarbonyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-57-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(3-furanylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-58-7 HCAPLUS

CN 3-Furancarboxamide, N-[[[(5S)-3-[6-(3-furanylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-60-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-63-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-64-5 HCAPLUS

CN 3-Isioxazolecarboxamide, 5-methyl-N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-67-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741722-68-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741722-70-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[(2-phenyl-4-thiazolyl)carbonyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-72-5 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[(5-phenyl-1,3,4-oxadiazol-2-yl)carbonyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-74-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-76-9 HCAPLUS

CN Carbamic acid, [[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(5-isoxazolylcarbonyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-79-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(2-benzofuranylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-80-5 HCAPLUS

CN 2-Benzofurancarboxamide, N-[[[(5S)-3-[6-(2-benzofuranylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-82-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741722-83-8 HCAPLUS

Updated Search

10773588

CN 1H-Pyrazole-5-carboxamide, N-[[[(5S)-3-[6-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-85-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-fluoro-6,7,8,9-tetrahydro-6-(5-isoxazolylcarbonyl)-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741722-87-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(2-benzothiazolylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741722-93-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-[(4-hydroxyphenyl)methylene]-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 741723-33-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-[(phenylmethoxy)acetyl]-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-49-9 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[6-(cyclopentylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

RN 741723-52-4 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(2-methyl-1-oxopropyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-54-6 HCAPLUS

CN Propanamide, 2-methyl-N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-(2-methyl-1-oxopropyl)-5-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741723-56-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(1-oxopropyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 741723-58-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(1-oxobutyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-60-4 HCAPLUS

CN Butanamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(1-oxobutyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 741723-62-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(2-thienylacetyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Updated Search

10773588


Absolute stereochemistry.



RN 741723-64-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-fluoro-6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-66-0 HCAPLUS

CN 3-Isioxazolecarboxamide, N-[[[(5S)-3-[4-fluoro-6,7,8,9-tetrahydro-6-[(5-methyl-3-isoxazolyl)carbonyl]-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741723-68-2 HCAPLUS


CN Acetamide, N-[[[(5S)-3-[6-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-4-fluoro-

Updated Search

10773588

6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-70-6 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[[[(5S)-3-[6-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-4-fluoro-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]-1,5-dimethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 741723-72-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[4-fluoro-6-(2-furanylcarbonyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741723-73-9 HCAPLUS


CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-oxo-5-(3-

Updated Search

10773588

pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 741723-74-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-6-oxo-5-(3-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 741723-75-1 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[6,7,8,9-tetrahydro-5-(5-isoxazolylcarbonyl)-6-oxo-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


1. The first step in the process of creating a new product is to identify a market need. This involves conducting market research to understand what consumers want and what problems they are facing. Once a need is identified, the next step is to develop a concept that addresses this need. This is often done through brainstorming sessions with a team of designers and engineers. The concept is then refined through prototyping and testing. Once a viable concept is developed, the next step is to create a detailed design. This involves specifying the materials, components, and manufacturing processes that will be used to create the product. The design is then approved by management and the production process begins. The final step in the process is to launch the product into the market. This involves creating a marketing plan and promoting the product through various channels. Once the product is launched, the company continues to monitor its performance and make improvements as needed.



RN 742101-55-9 HCAPLUS

CN Acetamide, N-[[[5S]-3-[6-(4-fluorobenzoyl)-6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 742101-56-0 HCAPLUS

Acetamide, N-[[[(5R)-2-oxo-3-[6,7,8,9-tetrahydro-5-oxo-6-(4-pyridinylcarbonyl)-5H-benzocyclohepten-2-yl]-5-oxazolidinyl)methyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10773588

IT 741721-99-3, (S)-5-Aminomethyl-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)oxazolidin-2-one hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tricyclic-substituted oxazolidinones and related compds. as antibacterial agents)
RN 741721-99-3 HCAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-(6,7,8,9-tetrahydro-5-oxo-5H-benzocyclohepten-2-yl)-, monohydrochloride, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L7 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:877311 HCAPLUS

DOCUMENT NUMBER: 140:128315

TITLE: Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials

AUTHOR(S): Johnson, Paul D.; Aristoff, Paul A.; Zurenko, Gary E.; Schaad, Ronda D.; Yagi, Betty H.; Ford, Charles W.; Hamel, Judith C.; Stapert, Douglas; Moerman, Judy K.

CORPORATE SOURCE: Discovery-Chemistry, Pharmacia Corporation, Kalamazoo, MI, 49001, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(23), 4197-4200

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:128315

AB Novel benzazepine oxazolidinone antibacterials were synthesized and evaluated against relevant susceptible and resistant organisms. The effect of ring nitrogen position and N-substitution on antibacterial activity is examined. Compds. thus tested included N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-2-(hydroxyacetyl)-1H-2-benzazepin-7-yl]-5-oxazolidinyl]methyl]acetamide, and N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl]acetamide.

IT 444587-56-8, N-[[[(5S)-3-(3-Formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-57-9, N-[[[(5S)-2-Oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]acetamide 444587-58-0

Updated Search

10773588


444587-60-4, N-[[[(5S)-3-(3-Acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-61-5
444587-62-6, N-[[[(5S)-3-(3-Benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-64-8
, N-[[[(5S)-2-Oxo-3-[2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]acetamide 444587-67-1
444587-68-2, N-[[[(5S)-2-Oxo-3-[2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]acetamide 648876-60-2
, N-[[[(5S)-2-Oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl]acetamide 648876-63-5

RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation and antibacterial activity of N-[[oxo(tetrahydrobenzazepinyl)oxazolidinyl]methyl]acetamide derivs.)

RN 444587-56-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-57-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-58-0 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 444587-60-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-61-5 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-62-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 444587-64-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-67-1 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-68-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 648876-60-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648876-63-5 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444588-27-6, N-[[[(5S)-2-Oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]acetamide

RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(preparation and antibacterial activity of N-[[[oxo(tetrahydrobenzazepinyl)oxazolidinyl]methyl]acetamide derivs.)


RN 444588-27-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10773588



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:575073 HCAPLUS

DOCUMENT NUMBER: 137:140512

TITLE: Preparation of benzoheterocyclyloxazolidinones as antibacterial agents.

INVENTOR(S): Johnson, Paul D.; Aristoff, Paul A.; Poel, Toni-Jo; Thomasco, Lisa M.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059115	A1	20020801	WO 2001-US42944	20011114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421583	AA	20020801	CA 2001-2421583	20011114
US 2002133021	A1	20020919	US 2001-992660	20011114
US 6972286	B2	20051206		
EP 1337530	A1	20030827	EP 2001-997007	20011114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517929	T2	20040617	JP 2002-559417	20011114
NZ 525918	A	20051125	NZ 2001-525918	20011114
US 2004176609	A1	20040909	US 2004-804389	20040319
US 2004186293	A1	20040923	US 2004-804380	20040319
PRIORITY APPLN. INFO.:				
			US 2000-249550P	P 20001117
			US 2001-992660	A3 20011114
			WO 2001-US42944	W 20011114

OTHER SOURCE(S): MARPAT 137:140512

GI

Updated Search

10773588



AB Title compds. [I; Y = NHC(:W)R1, OZ, SZ, NHZ; X = O, NR3, S, SO, SO2, S(O)(NR4); W = O, S; R1 = H, alkyl, cycloalkyl, alkoxy, alkylthio, amino; R2 = H, halo, alkyl; R3 = H, alkyl, aryl, Z, etc.; R4 = H, alkyl; Z = (substituted) (aromatic) heterocyclyl; with provisos], were prepared Thus, N-[[[(5S)-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-5-oxazolidinyl]methyl]acetamide (preparation given) and NaHCO3 in THF were treated with MeO2CCl with vigorous stirring. H2O was added and the mixture was stirred 1 h to give Me (-)-6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate. The latter showed a min. inhibitory concentration of 1 µg/mL against Streptococcus pneumoniae SPNE9912.

IT 444587-56-8P 444587-57-9P 444587-58-0P
444587-59-1P 444587-60-4P 444587-61-5P
444587-62-6P 444587-63-7P 444587-64-8P
444587-65-9P 444587-66-0P 444587-67-1P
444587-68-2P 444587-69-3P 444587-70-6P
444587-71-7P 444587-72-8P 444587-73-9P
444587-74-0P 444587-75-1P 444587-76-2P
444587-84-2P 444587-85-3P 444587-86-4P
444587-87-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)

RN 444587-56-8 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-57-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 444587-58-0 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-59-1 HCAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(hydroxyacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444587-60-4 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 444587-61-5 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-62-6 HCAPLUS

CN Acetamide, N-[[[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-63-7 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-(5-amino-1,3,4-thiadiazol-2-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10773588



RN 444587-64-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(methylsulfonyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-65-9 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[5-(methylthio)-1,3,4-thiadiazol-2-yl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-66-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 444587-67-1 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-, phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-68-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-69-3 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-[5-(formylamino)-1,3,4-thiadiazol-2-yl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 444587-70-6 HCAPLUS

CN Acetamide, N-[5-[7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-1,3,4-thiadiazol-2-yl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-71-7 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[(4-iodophenyl)acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-72-8 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[(3-(trifluoromethyl)phenyl)acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 444587-73-9 HCAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[7-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444587-74-0 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[[4-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-75-1 HCAPLUS

Updated Search

10773588

CN Acetamide, N-[[[(5S)-3-[3-(1,4-dioxopentyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444587-76-2 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-(1,5-dioxohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444587-84-2 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444587-85-3 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10773588



RN 444587-86-4 HCAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444587-87-5 HCAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444588-26-5P 444588-27-6P 444588-31-2P

444588-35-6P 444588-36-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoheterocyclyloxazolidinones as antibacterial agents)


RN 444588-26-5 HCAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search


10773588



RN 444588-27-6 HCAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444588-31-2 HCAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444588-35-6 HCAPLUS

CN Carbamic acid, [[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10773588



RN 444588-36-7 HCAPLUS
CN Carbamic acid, [[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

38.30	376.79
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-5.25	-5.25
-------	-------

FILE 'CAOLD' ENTERED AT 14:34:39 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

Updated Search

10773588

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 14:27:05 ON 26 SEP 2006)

FILE 'REGISTRY' ENTERED AT 14:27:11 ON 26 SEP 2006

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 4 S L4
L6 202 S L4 FULL

FILE 'HCAPLUS' ENTERED AT 14:34:11 ON 26 SEP 2006

L7 7 S L6

FILE 'CAOLD' ENTERED AT 14:34:39 ON 26 SEP 2006

=> s l6

L8 0 L6

=>

Updated Search